Alivus Life Sciences Ltd

- Glenmark Life Sciences has recently commissioned additional capacities of 208 KL at Ankleshwar and 18 KL pharmaceutical capacity at Dahej (started operations in Q2 FY '25). - Planned brownfield expansion includes adding an extra 60 KL pharma capacity at Ankleshwar in FY '26. - Planning to add a total of 160 KL capacity at Dahej, expected to come online in FY '26. - The Solapur facility is expected to add the first 200 KL of capacity by the end of Q3 FY '26 (though some references suggest FY '27). - Capex guidance for FY '25 is between INR 300 crore to INR 350 crore, which includes land purchase for R&D and other capacity expansions. - There is a mention of ongoing development of newer technology platforms (flow chemistry & other new platforms) with planned qualification and commercial runs in coming quarters/years.

- Glenmark Life Sciences Limited is currently a debt-free company and has not reported any existing debt (Page 9). - There is no mention of any ongoing or planned fundraising through debt in the call. - Capital expenditure for FY '25 is expected to be between INR 300-350 crores, financed presumably from operational cash flows (Page 9). - The company generated strong cash flows from operations of INR 134 crores in H1 FY '25 and has cash and equivalents of INR 446 crores, indicating sufficient liquidity (Page 5). - No indications or announcements of any equity fundraising were made during the call. - Overall, the company appears to be funding growth and expansion through internal accruals without resorting to debt or equity raising at this time.

- GLS expects high single-digit revenue growth for the full fiscal year FY '25, though earlier guidance was mid-teens, revised due to softness in Latin American markets (notably Argentina) and production disruptions. - Robust order book and strong demand environment are anticipated to drive stronger momentum in H2 FY '25. - Capacity expansions at Ankleshwar and Dahej will enhance volume deliveries in the current and coming years. - Additional pharma capacity (60 KL at Ankleshwar and 160 KL at Dahej) planned for FY '26 to support growth. - Medium-term growth is expected to improve, supported by new launches in North America, Russia, and other regions, plus expansion in CDMO business. - CDMO projects increasing from 3 to 5 next year will reduce lumpiness and contribute to faster growth. - Overall, the company targets early double-digit growth in generics and higher growth in CDMO post-FY '25.

- Glenmark Life Sciences expects high single-digit revenue growth for FY '25, revised down from earlier mid-teens guidance due to market softness in LatAm, especially Argentina. - Strong growth is anticipated in H2 FY '25, supported by a robust order book and recovery of production lost in Q2. - New CDMO projects are projected to add approximately $12 million in revenue at peak, expected to ramp up in H2 FY '26. - Several product launches in North America, Russia, and other markets are expected to drive growth in the coming years. - Base business demand remains steady except for Argentina, with potential for medium-term higher growth due to new CDMO projects and regional launches. - Margins are expected to remain stable around 28% EBITDA, with gross margins maintained at 52-55%. - Capacity expansions and debottlenecking planned for FY '26 will support higher volumes and further growth.

- Glenmark Life Sciences has a robust order book position heading into H2 FY '25, supporting expectations of strong growth. - For the fourth CDMO project starting Q3 FY '25, purchase orders (POs) for Q3 and Q4 are already in place. - The second new CDMO project expected to start in Q4 FY '25 might see a slight delay to the first half of next year due to regulatory approvals. - The base CDMO business with 3 existing projects has orders intact but is lumpy, with some servicing issues impacting order fulfillment in Q2; these are expected to be made up in early Q3. - Company is confident in fulfilling the existing order book despite production challenges. - Overall visibility is positive, with capacity utilization near 95%, meaning order fulfillment is nearly at full throttle.